menu
    • menu
    [{"orgOrder":0,"company":"SENJU PHARMACEUTICAL CO LTD","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Brimonidine Tartrate","moa":"Adrenergic receptor alpha-2","graph1":"Ophthalmology","graph2":"Approved","graph3":"SENJU PHARMACEUTICAL CO LTD","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"SENJU PHARMACEUTICAL CO LTD \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"SENJU PHARMACEUTICAL CO LTD \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"SENJU PHARMACEUTICAL CO LTD","sponsor":"Novaliq","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Perfluorohexyloctane","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"SENJU PHARMACEUTICAL CO LTD","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"SENJU PHARMACEUTICAL CO LTD \/ SENJU PHARMACEUTICAL CO LTD","highestDevelopmentStatusID":"12","companyTruncated":"SENJU PHARMACEUTICAL CO LTD \/ SENJU PHARMACEUTICAL CO LTD"},{"orgOrder":0,"company":"SENJU PHARMACEUTICAL CO LTD","sponsor":"Eyenovia","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Fonadelpar","moa":"","graph1":"Technology","graph2":"Approved","graph3":"SENJU PHARMACEUTICAL CO LTD","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"SENJU PHARMACEUTICAL CO LTD \/ SENJU PHARMACEUTICAL CO LTD","highestDevelopmentStatusID":"12","companyTruncated":"SENJU PHARMACEUTICAL CO LTD \/ SENJU PHARMACEUTICAL CO LTD"}]

    Find Clinical Drug Pipeline Developments & Deals by SENJU PHARMACEUTICAL CO LTD

    Menu

    SENJU PHARMACEUTICAL CO LTD

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            SENJU PHARMACEUTICAL CO LTD

                            Japan arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            SENJU PHARMACEUTICAL CO LTD

                            Japan arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fonadelpar

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Recipient : Eyenovia

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Eyenovia and Senju Pharmaceutical Sign Collaboration for Chronic Dry Eye Treatment

                            Details : both companies intend to work to develop Senju’s corneal epithelial candidate, SJP-0035, for use with Eyenovia’s Optejet dispensing technology, as a potential treatment for chronic dry eye disease.

                            Brand Name : SJP-0035

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 23, 2024

                            Lead Product(s) : Fonadelpar

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Recipient : Eyenovia

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            SENJU PHARMACEUTICAL CO LTD

                            Japan arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            SENJU PHARMACEUTICAL CO LTD

                            Japan arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Perfluorohexyloctane

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Recipient : Novaliq

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Senju Pharmaceutical and Novaliq Enter into License Agreement for NOV03 (Perfluorohexyloctane Ophthalmic Solut...

                            Details : Under the agreement, Senju acquires Japan rights to develop, manufacture, and commercialize NOV03 (perfluorohexyloctane ophthalmic solution), the first and only prescription treatment for signs and symptoms of dry eye disease that directly targets tear e...

                            Brand Name : NOV'03

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 13, 2023

                            Lead Product(s) : Perfluorohexyloctane

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Recipient : Novaliq

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            SENJU PHARMACEUTICAL CO LTD

                            Japan arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            SENJU PHARMACEUTICAL CO LTD

                            Japan arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Brimonidine Tartrate,Brinzolamide

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Sponsor : Otsuka Pharmaceutical

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Senju Pharmaceutical Launches New Combination Ophthalmic Solution for the Treatment of Glaucoma and Ocular Hyp...

                            Details : New combination ophthalmic solution for the treatment of glaucoma and ocular hypertension, AILAMIDE® Combination Ophthalmic Suspension has been launched in Japan on June 16, 2020.

                            Brand Name : Ailamide

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 16, 2020

                            Lead Product(s) : Brimonidine Tartrate,Brinzolamide

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Sponsor : Otsuka Pharmaceutical

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth